CHU Brugmann

Running trials

• Recruiting

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· Phase 3· Source

• Not yet recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

  NCT07760818· Phase 2· Source

• Recruiting

  Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)

  NCT07234838· Source

• Recruiting

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· Phase 3· Source

• Active, not recruiting

  Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections

  NCT04779970· Phase 2· Source

• Recruiting

  Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate.

  NCT07413315· Source

• Recruiting

  Better Understanding of Fatigue After STroke

  NCT06292377· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· Phase 3· Source

• Active, not recruiting

  Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre, open-label, randomised pragmatic clinical trial

  2023-506703-26-00· Phase 3· Source

• Recruiting

  Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer

  NCT06052332· Source

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Source

• Recruiting

  Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis

  NCT05072691· Source

• Active, not recruiting

  A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH

  2024-510626-89-00· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Multiple sclerosis1 recruiting
• Ovarian cancer1 recruiting
• Psoriasis1 recruiting
• Sickle cell disease1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source